Atnaujinkite slapukų nuostatas

El. knyga: 50 Studies Every Psychiatrist Should Know

3.64/5 (15 ratings by Goodreads)
Edited by (Resident Physician, Department of Psychiatry, Yale University School of Medicine), Edited by , Edited by (Professor of Psychiatry; Vice Chairman for Education, Residency Program Director and Chief of Geriatric Psychiatry, Case Western Reserve University Sch)
Kitos knygos pagal šią temą:
Kitos knygos pagal šią temą:

DRM apribojimai

  • Kopijuoti:

    neleidžiama

  • Spausdinti:

    neleidžiama

  • El. knygos naudojimas:

    Skaitmeninių teisių valdymas (DRM)
    Leidykla pateikė šią knygą šifruota forma, o tai reiškia, kad norint ją atrakinti ir perskaityti reikia įdiegti nemokamą programinę įrangą. Norint skaityti šią el. knygą, turite susikurti Adobe ID . Daugiau informacijos  čia. El. knygą galima atsisiųsti į 6 įrenginius (vienas vartotojas su tuo pačiu Adobe ID).

    Reikalinga programinė įranga
    Norint skaityti šią el. knygą mobiliajame įrenginyje (telefone ar planšetiniame kompiuteryje), turite įdiegti šią nemokamą programėlę: PocketBook Reader (iOS / Android)

    Norint skaityti šią el. knygą asmeniniame arba „Mac“ kompiuteryje, Jums reikalinga  Adobe Digital Editions “ (tai nemokama programa, specialiai sukurta el. knygoms. Tai nėra tas pats, kas „Adobe Reader“, kurią tikriausiai jau turite savo kompiuteryje.)

    Negalite skaityti šios el. knygos naudodami „Amazon Kindle“.

50 Studies Every Psychiatrist Should Know presents key studies that have shaped the practice of psychiatry. Selected using a rigorous methodology, the studies cover topics including: psychotic disorders, depressive disorders, women's mental health, child and adolescent disorders, and epidemiological studies. For each study, a concise summary is presented with an emphasis on the results and limitations of the study, and its implications for practice. An illustrative clinical case concludes each review, followed by brief information on other relevant studies. This book is a must-read for health care professionals and anyone who wants to learn more about the data behind clinical practice.
Preface xi
Acknowledgments xiii
About the Editors xv
Contributors xvii
Section 1 Anxiety Disorders
1 Cognitive Behavioral Therapy, Imipramine, or Their Combination for Panic Disorder
3(6)
Amanda Sun
Tobias Wasser
2 Fluoxetine, Comprehensive Cognitive Behavioral Therapy, and Placebo in Generalized Social Phobia
9(10)
Erin Habecker
Tobias Wasser
Section 2 Bipolar Disorder
3 Lithium Plus Valproate Combination versus Monotherapy for Relapse Prevention in Bipolar I Disorder (BALANCE)
19(5)
Joao Paulo De Aquino
Robert Beech
4 Mood Stabilizer Monotherapy versus Adjunctive Antidepressant for Bipolar Depression: The STEP-BD Trial
24(6)
Joao Paulo De Aquino
Robert Beech
5 Suicide Risk in Bipolar Disorder: Comparing Lithium, Divalproex, and Carbamazepine
30(5)
Rachel Katz
Robert Beech
6 The Long-Term Natural History of Bipolar I Disorder
35(8)
Zachary Engler
Robert Beech
Section 3 Child and Adolescent Disorders
7 The Multimodal Treatment Study of Children with Attention Deficit/Hyperactivity Disorder (MTA)
43(7)
Michael H. Bloch
8 Adolescents with SSRI-Resistant Depression: The TORDIA Trial
50(5)
Amalia Londono Tobon
Hanna E. Stevens
9 Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study
55(6)
J. Corey Williams
Hanna E. Stevens
10 Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety: CAMS
61(6)
David Saunders
Andres Martin
Jerome H. Taylor
11 Predictors of Suicidal Events: The Treatment of Adolescent Suicide Attempters (TASA) Study
67(6)
Michael Maksimowski
Zheala Qayyum
12 Cognitive Behavior Therapy, Sertraline, and Their Combination for Children and Adolescents with OCD
73(6)
Falisha Gilman
Zheala Qayyum
13 Initial Treatment of Bipolar I Disorder in Children and Adolescents: The TEAM Trial
79(5)
Stephanie Ng
Andres Martin
14 The Treatment for Adolescents with Depression Study (TADS)
84(9)
Zachary Engler
Zheala Qayyum
Section 4 Cognitive Disorders: Delirium/Dementia
15 Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease: CATIE-AD
93(7)
Adam P. Mecca
Rajesh R. Tampi
16 Risk of Death with Atypical Antipsychotic Medications for Dementia
100(6)
Adam P. Mecca
Rajesh R. Tampi
17 Treatment of Delirium in Hospitalized AIDS Patients: A Double-Blind Trial of Haloperidol, Chlorpromazine, and Lorazepam
106(6)
Amanda Sun
Rajesh R. Tampi
18 Memantine in Patients with Moderate to Severe Alzheimer's Disease Already Receiving Donepezil
112(9)
Brandon M. Kitay
Rajesh R. Tampi
Section 5 Epidemiology
19 Global Burden of Mental and Substance Use Disorders
121(6)
Stephanie Yarnell
Ellen Edens
20 Prevalence and Severity of Psychiatric Comorbidities: The National Comorbidity Survey Replication (NCS-R)
127(8)
Stephanie Yarnell
Ellen Edens
Section 6 Insomnia
21 Behavioral and/or Pharmacotherapy for Older Patients with Insomnia
135(8)
Robert Ross
Rajesh R. Tampi
Section 7 Major Depressive Disorder
22 Treatment of Depression in Patients with Alcohol or Drug Dependence: A Meta-Analysis
143(6)
J. Corey Williams
Gustavo A. Angarita Africano
23 Suicidality in Pediatric Patients Treated with Antidepressant Drugs: FDA Meta-Analysis
149(6)
David Saunders
Michael H. Bloch
24 National Institute of Mental Health (NIMH) Treatment of Depression Collaborative Research Program
155(6)
Joseph J. Taylor
Robert Ostroff
25 Efficacy and Safety of Electroconvulsive Therapy in Depressive Disorders: A Systematic Review and Meta-Analysis
161(6)
Joseph J. Taylor
Robert Ostroff
26 Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration
167(6)
Michael Maksimowski
Zheala Qayyum
27 Sequenced Treatment Alternatives to Relieve Depression: STARD
173(6)
Eric Lin
Pochu Ho
28 Cognitive Therapy versus Medication in the Treatment of Moderate to Severe Depression
179(8)
Daniel Barron
Robert Ostroff
Section 8 Obsessive-Compulsive Disorder
29 Exposure and Ritual Prevention, Clomipramine, or Their Combination for Obsessive-Compulsive Disorder
187(5)
Brandon M. Kitay
Michael H. Bloch
30 Meta-Analysis of the Dose-Response Relationship of SSRIs in Adult Patients with Obsessive-Compulsive Disorder
192(9)
Eunice Yuen
Michael H. Bloch
Section 9 Personality Disorders
31 Psychotherapy for Borderline Personality Disorder: A Multiwave Study
201(6)
David Grunwald
Erica Robinson
Sarah Fineberg
32 Dialectical Behavior Therapy versus Community Treatment by Experts for Reducing Suicidal Behaviors among Patients with Borderline Personality Disorder
207(6)
David Saunders
Erica Robinson
Sarah Fineberg
33 Ten-Year Course of Borderline Personality Disorder: The Collaborative Longitudinal Personality Disorders Study
213(8)
Kevin Johnson
Erica Robinson
Sarah Fineberg
Section 10 Psychiatry in Primary Care
34 Depressive Symptoms and Health-Related Quality of Life: The Heart and Soul Study
221(5)
Amalia Londono Tobon
Catherine Chiles
35 The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) Trial
226(7)
Nikhil Gupta
Catherine Chiles
Section 11 Women's Mental Health
36 Buprenorphine versus Methadone During Pregnancy: The MOTHER Trial
233(8)
Rachel Wurmser
Kirsten Wilkins
Section 12 Schizophrenia
37 QTc-Interval Abnormalities and Psychotropic Drug Therapy in Psychiatric Patients
241(6)
Amanda Sun
Vinod H. Srihari
38 Tardive Dyskinesia with Atypical versus Conventional Antipsychotic Medications
247(6)
Emma Lo
Cenk Tek
39 Effectiveness of Antipsychotics in the Treatment of Schizophrenia: CATIE Phase 1
253(7)
Chadrick Lane
Mohini Ranganathan
40 Clozapine for Treatment-Resistant Schizophrenia
260(6)
Chadrick Lane
Vinod H. Srihari
41 Effectiveness of Clozapine versus Other Atypical Antipsychotics: Clinical Antipsychotic Trials for Interventions Effectiveness (CATIE)
266(8)
Eunice Yuen
Cenk Tek
42 Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death
274(5)
Hamilton Gaiani
Cenk Tek
43 Switching Antipsychotics to Reduce Metabolic Risk: The CAMP Trial
279(6)
Eric Lin
John Cahill
44 Cost Utility of Atypical Antipsychotics: CUtLASS-1
285(5)
Nikhil Gupta
John Cahill
45 North American Prodrome Longitudinal Study
290(5)
Nikhil Gupta
Vinod H. Srihari
46 Clozapine for Suicidality in Schizophrenia: The International Suicide Prevention Trial (InterSePT)
295(5)
Daniel Barron
Noah Capurso
47 A Cohort Study of Oral and Depot Antipsychotics after First Hospitalization for Schizophrenia
300(9)
Stephanie Ng
Cenk Tek
Section 13 Substance Use Disorders
48 Methadone Maintenance versus Detoxification and Psychosocial Treatment for Opioid Dependence: The M180 Study
309(5)
Hamilton Gaiani
Srinivas Muvvala
49 Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence: The COMBINE Study
314(7)
Kevin Johnson
Srinivas Muvvala
50 Levomethadyl Acetate versus Buprenorphine versus Methadone for Opioid Dependence
321(6)
Robert Ross
Brian Fuehrlein
Index 327
Dr. Ish P. Bhalla earned his BS cum laude from Case Western Reserve University and his MD from the University of Toledo College of Medicine. He completed his psychiatry residency from Yale University and is currently a forensic psychiatry fellow at Yale. He plans to pursue a career in medical education, academic psychiatry, healthcare policy, and services research. He will be pursuing a health policy fellowship as a National Clinician Scholar at The University of California, Los Angeles.

Dr. Rajesh R. Tampi is a Professor of Psychiatry at Case Western Reserve University School of Medicine and the Vice Chairman for Education and Faculty Development, Residency Program Director, and the Chief of Geriatric Psychiatry at MetroHealth, Cleveland, Ohio. He is also the President of the International Medical Graduates (IMG) Caucus of the American Psychiatric Association and the Secretary and Treasurer of the American Association for Geriatric Psychiatry (AAGP).

Dr. Vinod H. Srihari developed and

oversees Yale University's Evidence-Based Mental Health curriculum, which has been recognized as a national model by the American Association of Directors of Psychiatric Residency Training (AADPRT). He continues to enjoy the challenge of using population based evidence in the care of individual patients, teaching and learning how to make better use of the evidence, and designing clinical research in response to public health challenges.